PaclitaxelAntineoplastic Agents, PhytogenicAntineoplastic AgentsRadiation DosageRadiation, IonizingRadiation InjuriesCell Line, TumorDose-Response Relationship, RadiationDrug Screening Assays, AntitumorRadiation ToleranceNeoplasmsRadiationDoxorubicinDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsRadiation ProtectionCisplatinRadiation MonitoringCarboplatinApoptosisCell SurvivalDose-Response Relationship, DrugBreast NeoplasmsDrug Delivery SystemsDrug Administration ScheduleTumor Cells, CulturedMice, NudeAntibiotics, AntineoplasticOvarian NeoplasmsDrug CarriersXenograft Model Antitumor AssaysTubulin ModulatorsRadiation OncologyP-GlycoproteinCombined Modality TherapyDrug SynergismTreatment OutcomeRadiation-Sensitizing AgentsLung NeoplasmsDrug Resistance, MultipleGamma RaysCell ProliferationCosmic RadiationTaxoidsRadiation Injuries, ExperimentalEtoposideTime FactorsInhibitory Concentration 50DNA DamageTaxusRadiation PneumonitisRadiotherapyCarcinoma, Non-Small-Cell LungNeoplasms, Radiation-InducedInfusions, IntravenousCell CycleCamptothecinNanoparticlesFluorouracilRadiotherapy DosageDeoxycytidineBackground RadiationEllipticinesVinblastineUltraviolet RaysTubulinMolecular StructureRadiometryTopotecanBridged CompoundsPlatinumNeoplasm TransplantationDisease-Free SurvivalSurvival AnalysisGene Expression Regulation, NeoplasticDrug DesignAdenocarcinomaEnzyme InhibitorsRadiation EffectsRadiation-Protective AgentsProdrugsGenitalia, FemaleArea Under CurveMaximum Tolerated DoseNeutropeniaEpothilonesOrganoplatinum CompoundsNeoplasms, ExperimentalAntimetabolites, AntineoplasticProto-Oncogene Proteins c-bcl-2Cell DivisionNanomedicineSurvival RateTumor Suppressor Protein p53Neoplasm StagingPharmaceutical VehiclesDrug Evaluation, PreclinicalMicrotubulesBlotting, WesternNanocapsules